Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Buy at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other research analysts have also recently weighed in on the stock. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $44.90 on Friday. The firm has a 50 day simple moving average of $46.18 and a 200-day simple moving average of $42.66. Kiniksa Pharmaceuticals International has a 1-year low of $19.62 and a 1-year high of $50.03. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of 60.68 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same period last year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 65.0% on a year-over-year basis. On average, equities analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 7,278 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $50.01, for a total value of $363,972.78. Following the completion of the sale, the chief executive officer directly owned 7,278 shares of the company’s stock, valued at approximately $363,972.78. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the sale, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at $523,082.08. The trade was a 59.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,479 shares of company stock worth $2,832,812 in the last three months. 53.48% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in Kiniksa Pharmaceuticals International by 281.9% in the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock worth $3,028,000 after acquiring an additional 57,566 shares during the period. Fisher Asset Management LLC grew its stake in Kiniksa Pharmaceuticals International by 176.1% in the 3rd quarter. Fisher Asset Management LLC now owns 282,288 shares of the company’s stock worth $10,961,000 after acquiring an additional 180,029 shares during the period. Aberdeen Group plc purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $6,163,000. Essex Investment Management Co. LLC grew its stake in Kiniksa Pharmaceuticals International by 44.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock worth $9,603,000 after acquiring an additional 75,864 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $1,480,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.